We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00600886
First Posted: January 25, 2008
Last Update Posted: July 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
  Purpose

The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment.

The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months.

Following one year of treatment patients could proceed into the study extension.

Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) were switched to the other treatment arm at month 13.


Condition Intervention Phase
Acromegaly Drug: Pasireotide Drug: Octreotide Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 [ Time Frame: 12 months ]

    Percentage of participants with a reduction of mean GH levels to <2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.

    Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.



Secondary Outcome Measures:
  • Percentage of Participants With a Reduction of Mean GH Level to < 2.5μg/L [ Time Frame: 12 Months ]

    Percentage of participants with a reduction of mean GH levels to < 2.5μg/L (based on a 5-point 2-hour profile).

    Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.


  • Change From Baseline in Tumor Volume at 12 Months [ Time Frame: Baseline, 12 Months ]
    Absolute and percentage change from baseline in tumor volume (assessed by pituitary MRI) Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.

  • Percentage of Participants With Normalization of IGF-1 [ Time Frame: 12 Months ]
    Percentage of participants with normalization of sex- and age-adjusted IGF-1. Post surgery = patients with prior surgery but no previous medical treatment for acromegaly De novo = patients with de novo disease who refused pituitary surgery or for whom pituitary surgery was contraindicated.

  • Percentage of Participants With a Reduction of Mean GH Level to < 2.5μg/L and Normalization of IGF-1 [ Time Frame: Months 3, 6, 9, 12, 16, 19, 22, 25 ]

    Percentage of participants with a reduction of mean GH levels to < 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1.

    Denominator for time points up to Month 12 is the Full Analysis Set (FAS). Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover. Analysis was based on data up to crossover (i.e., included data from both blinded core & ext. phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included.)


  • Summary of Mean GH Values [ Time Frame: Baseline, Months 3, 6, 9, 12, 16, 19, 22, 25 ]
    Mean GH levels (based on a 5-point profile over 2 hours). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Time to First Response for Patients Achieving a Reduction of Mean GH Level to < 2.5 μg/L and Normalization of IGF-1 (No. of Responders: Pasireotite LAR = 81, Octreotide LAR = 63) ) [ Time Frame: Up to 26 months ]
    Time to first response for patients achieving a reduction of mean GH level to < 2.5 μg/L and normalization of IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Severity Scores of Acromegaly Symptoms [ Time Frame: Baseline, Months 12, 25 ]
    Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia). Symptoms were scored from 0 (no symptom) to 4 (very severe). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Ring Size [ Time Frame: Baseline, Months 12, 25 ]
    Ring size (based on jeweler's finger gauge). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Health-related Quality-of-life as Measured by the AcroQoL Questionnaire [ Time Frame: Baseline, Months 12, 25 ]
    Acromegalyy quality of life (AcroQoL) total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Total scores range from 0 to 100. Higher scores represent better quality of life. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Summary of Prolactin Levels [ Time Frame: Baseline, Months 12, 25 ]
    Prolactin Levels. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Duration of Response for Patients Achieving a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 at Month 12 (No. of Responders: Pasireotide LAR = 51, Octreotide LAR = 32) [ Time Frame: Up to 26 months ]

    The duration of response is defined as the time from the date that patient first met and maintained the response criteria based on primary efficacy variable to the date that patient lost response status.

    Median and corresponding 95% CI are derived based on Kaplan-Meier method. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).


  • Pasireotide Trough Concentrations by Incident Dose [ Time Frame: Months 1 - 12 ]

    Pasireotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.

    5 patients with evaluable PK data in the pasireotide arm received erroneously 20 mg pasireotide LAR at baseline.


  • Octreotide Trough Concentrations by Incident Dose [ Time Frame: Months 1 - 12 ]
    Octreotide LAR trough concentrations by incident dose (last dose administered prior to PK sample collection). PK observations with missing concentrations, missing dose, missing elapsed time or an elapsed time from previous injection outside of 28±2 days window were excluded.

  • Percentage of Participants With a Reduction of Mean GH Level to < 2.5μg/L and Normalization of IGF-1 After Crossover [ Time Frame: Months 3, 6, 9, 12 after crossover ]
    Percentage of participants with a reduction of mean GH levels to < 2.5μg/L (based on a 5-point 2-hour profile) and normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).

  • Percentage of Participants With a Reduction of Mean GH Level to < 2.5μg/L [ Time Frame: Months 3, 6, 9, 12, 16, 19, 22, 25 ]

    Percentage of participants with a reduction of mean GH levels to < 2.5μg/L (based on a 5-point 2-hour profile).

    Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the Full Analysis Set. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.


  • Percentage of Participants With Normalization of IGF-1 [ Time Frame: Months 3, 6, 9, 12, 16, 19, 22, 25 ]
    Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included). Denominator for time points up to Month 12 is the FAS. Denominator for time points after Month 12 excludes patients who completed the core and did not enter the extension. Patients who discontinued were considered non-responders for the time points after discontinuation, patients who crossed over were considered non-responders for all time points after crossover.

  • Change From Baseline in Tumor Volume [ Time Frame: Baseline, months 6, 12, 19, 25 ]
    Percentage change from baseline in tumor volume (assessed by pituitary MRI). Analysis was based on data up to crossover (i.e., included data from both blinded core and extension phase up to 26 Months for patients who continued the same treatment in the extension. For patients who switched to the other treatment, only data collected before crossover was included).

  • Percentage of Participants With a Reduction of Mean GH Level to < 2.5μg/L After Crossover [ Time Frame: Months 3, 6, 9, 12 after crossover ]
    Percentage of participants with a reduction of mean GH levels to < 2.5μg/L (based on a 5-point 2-hour profile). Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).

  • Percentage of Participants With Normalization of IGF-1 After Crossover [ Time Frame: Months 3, 6, 9, 12 after crossover ]
    Percentage of participants with normalization of sex- and age-adjusted IGF-1. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Denominator for all time points is the Crossover Analysis Set (CAS).

  • Summary of Mean GH Values After Crossover [ Time Frame: Extension baseline, months 3, 6, 9, 12 after crossover ]
    Mean GH levels (based on a 5-point profile over 2 hours). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).

  • Change From Extension Baseline in Tumor Volume After Crossover [ Time Frame: Extension baseline, months 6, 12 after crossover ]

    Percentage change from extension baseline in tumor volume (assessed by pituitary MRI).

    Extension baseline was defined as last assessment prior to the administration of the new treatment after crossover. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).


  • Severity Scores of Acromegaly Symptoms After Crossover [ Time Frame: Extension baseline, month 12 after crossover ]

    Severity scores of acromegaly symptoms (Headache, Fatigue, Perspiration, Paresthesias, Osteoarthralgia).

    Symptoms were scored from 0 (no symptom) to 4 (very severe). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over).


  • Ring Size After Crossover [ Time Frame: Extension baseline, month 12 after crossover ]
    Ring size (based on jeweler's finger gauge). Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). BL = baseline, LH = left hand, RH = right hand, CO = crossover

  • Health-related Quality-of-life as Measured by the AcroQoL Questionnaire After Crossover [ Time Frame: Extension baseline, months 12 after crossover ]
    AcroQoL total scores. The AcroQoL questionnaire is unidimensional and contains 22 items divided in two scales: one that evaluates physical aspects (eight items) and another one that evaluates psychological aspects (14 items). The scoring of the questionnaire was performed as specified by the instrument developers. Extension baseline was defined as last measurement prior to the start of crossover treatment. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Total scores range from 0 to 100. Higher scores represent better quality of life.

  • Summary of Prolactin Levels After Crossover [ Time Frame: Extension baseline, month 12 after crossover ]
    Prolactin (PRL) levels. Analysis was based on data after crossover (i.e., included data from blinded extension phase collected after the crossover time point for patients who crossed over). Extension baseline was defined as last measurement prior to the start of crossover treatment.


Enrollment: 358
Actual Study Start Date: February 11, 2008
Study Completion Date: March 11, 2016
Primary Completion Date: March 11, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pasireotide LAR
Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
Drug: Pasireotide
Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
Other Name: SOM230
Active Comparator: Octreotide LAR
Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
Drug: Octreotide
Octreotide LAR - i.m. depot injection given once every 28 days.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Patients with active acromegaly (based on elevated GH and IGF-1 levels)
  • Patients who have undergone one or more pituitary surgeries, but have not been treated medically, or de-novo patients presenting a visible pituitary adenoma on MRI and who refuse pituitary surgery or for whom pituitary surgery is contraindicated
  • Patients for whom written informed consent to participate in the study has been obtained prior to any study related activity

Exclusion criteria:

  • Patients who are being or were treated with octreotide, lanreotide, dopamine agonists or GH antagonists with the exception of a single dose of short-acting octrotide or short-acting dopamine agonists. In case of a single dose of short-acting octrotide, the dose should not be used to predict the response to the octretide treatment. The single dose of short-acting octreotide or short-acting dopamine agonists should not be administered in the 3 days prior to randomization
  • Patients with compression of the optic chiasm causing any visual field defect
  • Patients who have received pituitary irradiation within the last ten years prior to visit 1
  • Poorly controlled diabetic patients

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600886


  Hide Study Locations
Locations
United States, California
Cedars Sinai Medical Center The Pituitary Center
Los Angeles, California, United States, 90048
University of California at Los Angeles Division of Endocrinology
Los Angeles, California, United States, 90095
Stanford University Medical Center Stanford Cancer Center (3)
Stanford, California, United States, 94304
United States, Florida
University of Florida SC
Gainesville, Florida, United States, 32610
United States, Maryland
Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv.
Baltimore, Maryland, United States, 21205
United States, Michigan
University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes
Ann Arbor, Michigan, United States, 48109-0944
United States, New York
Columbia University Medical Center- New York Presbyterian Dept. of CU Collegeof Phys&Sur
New York, New York, United States, 10032
Northport VA Medical Center CSOM230C2305
Northport, New York, United States, 11768
United States, Oregon
Oregon Health & Sciences University DeptofOregonHealth&Sciences(3)
Portland, Oregon, United States, 97201
United States, Pennsylvania
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania, United States, 15212
United States, Texas
University of Texas Southwestern Medical Center Danziger Research Bldg.
Dallas, Texas, United States, 75390
University of Texas/MD Anderson Cancer Center Regulatory -12
Houston, Texas, United States, 77030-4009
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Washington
Swedish Medical Center Dept.ofSeattle Neuroscience(2)
Seattle, Washington, United States
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1405BCH
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina, 1425EKP
Novartis Investigative Site
Buenos Aires, Argentina, C1232AAC
Belgium
Novartis Investigative Site
Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1070
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Brazil
Novartis Investigative Site
Fortaleza, CE, Brazil, 60430 370
Novartis Investigative Site
Brasilia, DF, Brazil, 70840-901
Novartis Investigative Site
Sao Luis, MA, Brazil, 65020-070
Novartis Investigative Site
Curitiba, PR, Brazil, 80060-900
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 21941-913
Novartis Investigative Site
Sao Paulo, SP, Brazil, 05403-000
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 2W5
Novartis Investigative Site
Sherbrooke, Quebec, Canada, J1H 5N4
China, Beijing
Novartis Investigative Site
Beijing, Beijing, China, 100730
China
Novartis Investigative Site
Shanghai, China, 200025
Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia, 111411
Czechia
Novartis Investigative Site
Prague 2, Czech republic, Czechia, 128 02
Denmark
Novartis Investigative Site
Aalborg, Denmark, DK-9100
Novartis Investigative Site
Copenhagen, Denmark, DK-2100
France
Novartis Investigative Site
Bois Guillaume Cedex, France, 76233
Novartis Investigative Site
Bron Cedex, France, 69677
Novartis Investigative Site
Le Kremlin Bicetre, France, 94275
Novartis Investigative Site
Marseille cedex 05, France, 13385
Novartis Investigative Site
Montpellier Cedex 5, France, 34295
Novartis Investigative Site
Paris, France, 75014
Novartis Investigative Site
Pessac Cedex, France, 33604
Germany
Novartis Investigative Site
Berlin, Germany, 10098
Novartis Investigative Site
Berlin, Germany, 12203
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45122
Novartis Investigative Site
Muenchen, Germany, 80336
Greece
Novartis Investigative Site
Athens, GR, Greece, 115 27
Novartis Investigative Site
Pireas, Greece, 18537
Hungary
Novartis Investigative Site
Budapest, Hungary, 1085
Israel
Novartis Investigative Site
Jerusalem, Israel, 91120
Novartis Investigative Site
Petach Tikva, Israel, 49100
Italy
Novartis Investigative Site
Cona, FE, Italy, 44100
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Padova, PD, Italy, 35128
Novartis Investigative Site
Pisa, PI, Italy, 56124
Novartis Investigative Site
Roma, RM, Italy, 00168
Novartis Investigative Site
Torino, TO, Italy, 10126
Novartis Investigative Site
Napoli, Italy, 80131
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 03722
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 05505
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Republic of, 130-872
Mexico
Novartis Investigative Site
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site
México, Distrito Federal, Mexico, 06720
Netherlands
Novartis Investigative Site
Nijmegen, Netherlands, 6525 GA
Novartis Investigative Site
Rotterdam, Netherlands, 3015 CE
Norway
Novartis Investigative Site
Bergen, Norway, NO-5021
Novartis Investigative Site
Oslo, Norway, NO-0379
Poland
Novartis Investigative Site
Krakow, Poland, 31-531
Novartis Investigative Site
Warszawa, Poland, 01 809
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 117036
Novartis Investigative Site
Moscow, Russian Federation, 119992
Novartis Investigative Site
Saint Petersburg, Russian Federation, 197341
Novartis Investigative Site
Saint-Petersburg, Russian Federation, 194044
Spain
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site
Hospitalet de Llobregat, Barcelona, Spain, 08907
Novartis Investigative Site
Alicante, Comunidad Valenciana, Spain, 03010
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Sweden
Novartis Investigative Site
Linkoping, Sweden, SE-581 85
Novartis Investigative Site
Malmö, Sweden, SE-205 02
Novartis Investigative Site
Uppsala, Sweden, SE-751 85
Switzerland
Novartis Investigative Site
St. Gallen, Switzerland, 9007
Taiwan
Novartis Investigative Site
Lin-Kou, Taiwan, 33305
Novartis Investigative Site
Taichung, Taiwan, 40705
Novartis Investigative Site
Taipei, Taiwan, 10002
Turkey
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Erzurum, Turkey, 25240
United Kingdom
Novartis Investigative Site
Leeds, United Kingdom, LS1 3EX
Novartis Investigative Site
Liverpool, United Kingdom, L7 8XP
Novartis Investigative Site
London, United Kingdom, EC1A 7BE
Novartis Investigative Site
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Chair: Novartis Novartis
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00600886     History of Changes
Other Study ID Numbers: CSOM230C2305
2007-001972-36 ( EudraCT Number )
First Submitted: January 14, 2008
First Posted: January 25, 2008
Results First Submitted: December 19, 2014
Results First Posted: January 30, 2015
Last Update Posted: July 2, 2017
Last Verified: June 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Acromegaly,
adult,
growth hormone,
insulin-like growth factor I,
somatostatin analogue

Additional relevant MeSH terms:
Acromegaly
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Octreotide
Pasireotide
Somatostatin
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs